{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-031189","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.539769+00:00","generated_at":"2026-06-16T22:39:44.080239+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Blue Water Vaccines acquires Veru's ENTADFI for $100M; plans name change to Blue Water Biotech","bullets":["Total consideration $100M: $20M upfront (tranches through Sept 2024) plus up to $80M in sales milestones.","Assumes royalty and milestone obligations up to $22.5M from prior agreement.","Acquires ~125,000 bottles of ENTADFI, an FDA-approved BPH treatment.","Company will change name to Blue Water Biotech; CEO Joseph Hernandez leads.","Frank Jaeger to lead commercialization; previously doubled AndroGel sales to $1.3B."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-031189","json":"https://secwatch.observer/filing/0001213900-23-031189.json","markdown":"https://secwatch.observer/filing/0001213900-23-031189.md","text":"https://secwatch.observer/filing/0001213900-23-031189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T22:39:44.080239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ced50eb72a70c7cd9b2ba754194d4749fed5cb8","claim":"Onconetix, Inc. completed an acquisition involving Veru Inc. for $100,000,000 (closed 2023-04-19).","evidence_excerpt":"of the Transaction The Company purchased substantially all of the Seller’s assets, rights and property related to the ENTADFI TM Business for a total possible consideration of $100,000,000 (as described below). The ENTADFI TM Business capitalizes on the demonstrable success of the FDA-approved drug ENTADFI TM for treating benign prostatic hyperplasia and","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Veru Inc."},{"label":"Consideration","value":"$100,000,000"},{"label":"Closing","value":"2023-04-19"}],"fact_type":"ma_transaction"},{"claim_id":"5ce55eb0486928a3422556f023e682d13b437682","claim":"Onconetix, Inc. entered into Purchase Agreement with Veru Inc. valued at total possible consideration of $100,000,000 (effective 2023-04-19).","evidence_excerpt":"On April 19, 2023, Blue Water Vaccines Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the \"Purchase Agreement\") with Veru Inc., a Wisconsin corporation (the \"Seller\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Veru Inc."},{"label":"Value","value":"total possible consideration of $100,000,000"},{"label":"Effective","value":"2023-04-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}